

GERM

ETFMG Treatments Testing and Advancements ETF

Fund Description

GERM tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases.

FactSet Analyst Report

GERM provides unique exposure to a subsector of biotech industry. The passively-managed fund holds companies that test and develop treatments against infectious diseases by focusing on companies at the forefront of R&D, vaccines, therapies and testing technologies. Companies included in the index must meet minimum market-cap and liquidity requirements. Also, companies must have an operating company structure, no pass-through securities. Selected stocks are weighted in tiers wherein the top five largest constituents receives 30% weight in the index in aggregate with an equal weight of 6% each, while the remaining securities are weighted by market-cap with 4% single security cap. Companies with market-cap of \$15 billion or more are also equally weighted, receiving 10% portion of the portfolio in aggregate. The index is rebalanced and reconstituted every quarter.

